LifeStance Health Group (NASDAQ:LFST) Stock Rating Upgraded by Wall Street Zen

LifeStance Health Group (NASDAQ:LFST) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Friday.

LFST has been the topic of several other research reports. BMO Capital Markets initiated coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price target on the stock. UBS Group lifted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. BTIG Research increased their price target on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

LifeStance Health Group Trading Down 0.4%

Shares of LifeStance Health Group stock opened at $7.34 on Friday. The firm’s 50 day moving average is $6.88 and its 200 day moving average is $5.72. The firm has a market capitalization of $2.86 billion, a PE ratio of -244.67 and a beta of 1.12. LifeStance Health Group has a 1 year low of $3.74 and a 1 year high of $8.30. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The firm had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. During the same period last year, the company earned ($0.02) earnings per share. The business’s quarterly revenue was up 16.3% on a year-over-year basis. Equities research analysts forecast that LifeStance Health Group will post -0.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, insider Ann Varanakis sold 50,000 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the sale, the insider directly owned 315,610 shares in the company, valued at $2,177,709. The trade was a 13.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert Bessler sold 119,942 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the sale, the director owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. This trade represents a 8.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 327,326 shares of company stock valued at $2,259,317 over the last quarter. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bayesian Capital Management LP bought a new stake in LifeStance Health Group in the second quarter worth $52,000. Blair William & Co. IL bought a new stake in shares of LifeStance Health Group in the second quarter valued at about $70,000. Public Employees Retirement System of Ohio purchased a new stake in LifeStance Health Group in the second quarter worth about $70,000. Vanguard Personalized Indexing Management LLC bought a new position in LifeStance Health Group during the 3rd quarter worth about $72,000. Finally, CIBC Bancorp USA Inc. bought a new position in LifeStance Health Group during the 3rd quarter worth about $78,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.